









Annual Tehran Heart Center Congress

7th CRITICAL CARDIOVASCULAR CARE

دوازدهمین کنگره سالیانه مرکز قلب تهران




Deferred Stenting After MI

By: Saeed Nourian

Endovascularist and Phlebologist

Assistant Professor of Iran UMS, Firoozgar Hospital










Case Vignette

- A 45-year-old man presented to ED
- Acute anterior-wall MI of 8 hours duration
- HTN & C/S
- CAG showed a significant stenosis with grade IV thrombus in proximal LAD with TIMI 2 flow










- Due to high thrombus burden, stenting was deferred and the patient was put on IV eptifibatide infusion for 18 hours followed by subcutaneous LMWH twice daily.
- Rescue PCI was planned in case the patient developed chest pain.
- After 5 days, his angiogram showed moderate stenosis and the thrombus in LAD was almost absent with improved TIMI 3 flow.











Introduction and Definition

- Deferred stenting is a strategy that aims to postpone stent placement for a fixed time window after stable distal flow has been achieved.
- Other terminology used in the literature for a procrastinated stenting approach include delayed PCI and secondary PCI.





- In a fraction of patients reduced coronary blood flow (slow flow or no reflow) is seen despite epicardial vessel patency with PCI, and this is associated with a worse prognosis.
- Distal migration of thrombus and atherosclerotic debris are important contributors to interventional slow/no reflow.





- Presence of residual thrombus even after manual aspiration is one of the pitfalls and it predicts poor outcomes.
- Thrombus grading on angiography is done by the Gibson's angiographic score/TIMI criteria.
- A thrombus grade higher than 3 is usually considered as high thrombus burden.





Table 1: Thrombolysis in MI Grading for Thrombus Burden

Grade	Characteristics
0	No angiographic evidence of thrombus
1	Possible thrombus: reduced contrast density or haziness, irregular lesion contour, a smooth convex meniscus at the site of a total occlusion suggestive but not diagnostic of thrombus
2	Definite thrombus, with greatest dimensions ≤1/2 the vessel diameter
3	Definite thrombus, with greatest linear dimension >1/2 but <2 vessel diameters
4	Definite thrombus, with the largest dimension ≥2 vessel diameters
5	Total thrombotic occlusion

Source: Gibson et al. 2001.6





- This time of deferment has multiple benefits:
 - Gradual clearing of the thrombus,
 - Improvement of microvascular flow,
 - Reduction of vasospasm
 - Prevention of distal embolisation,
 - Avoidance of slow flow/no reflow
 - Attenuated periprocedural MIs.
- Indeed, data suggests the coexistence of thrombus and spasm and hence a deferred strategy can lead to better stent selection (large and short stents).





Approach

- There is a possible risk of reocclusion during the waiting period which can be mitigated by parenteral anticoagulants and GP IIb/IIIa inhibitors.
- A rescue PCI should be considered if necessary.
- A prolonged systemic anticoagulation can increase the risk of bleeding which can be detrimental.
- However, the use of the CRUSADE bleeding risk score can help to assess the baseline bleeding risk of the patient.

Score
haematocrit, % 9 7
9 3
9 2
0
ne clearance, ^a mL/min
39
35 28
28 0 17
20 7
o
te (b.p.m.)
0
I
3
6
10
20
9
CHF at presentation
0 7
0
mellitus
0
plood pressure, mmHg
3
5
mellitus plood pressure, mmHg 10 80 20 10 10 10 10 10 10 10 10 10 10 10 10 10





- Scores <20 indicate a very low risk of in-hospital bleeding.
- Score >20 the use of GP IIb/IIIa inhibitor infusion should be avoided.
- Score >50 are at a very high risk of bleeding and the duration of LMWH duration should be reduced to 72 hours instead of the standard proposed duration of 5–7 days.





- Minimally invasive mechanical intervention (MIMI) is an adjuvant technique during primary PCI before deferring stent placement in arteries with TIMI 0–1 flow.
- The strategy entails the use of a guidewire, an undersized balloon catheter and thrombus aspiration to establish distal coronary flow.
- The aim is to restore the flow with minimal forward propagation of thrombus.





Review of Literatures...

- Predictors of greater benefit from deferred stenting
 - Male sex,
 - younger age,
 - larger size of culprit artery
 - higher thrombus burden at baseline
- In a Danish pilot study, the need for subsequent stenting was reduced by 38% without any risk of reocclusion at 3 months with a deferred strategy.
- In Ke et al., subsequent stents were avoided in 23% of patients.





- In a French study, Souteyrand et al. used OCT to guide deferred stenting.
- The study tested the safety of three different strategies acute (<2 days), early (up to 7 days) and late deferral (up to 1 month) in the setting of STEMI with large thrombus burden on angiogram.
- There were no MACE recorded between initial and final procedure.
- The thrombus presence as assessed by OCT continued to diminish from acute phase (94.1%) to early phase (78%) to late phase (32%).
- This study demonstrated that OCT-guided postponement of stent implantation led to good procedural outcomes with 100% success and alleviation of no-reflow events.





- The SUPER-MIMI study tested a longer deferral time of 7 days in 155 patients with STEMI.
 - There was an improvement in TIMI flow,
 - Decrease in thrombus burden
 - Stenosis severity diminished.
- More importantly, stenting was also avoided in 38% cases with a minimal chance of reocclusion (1.3%).





- In the DEFER-STEMI study, patients were randomized to either conventional stenting or deferred stenting.
- Patients with STEMI along with angiographic or clinical features for risk of slow flow/no reflow were enrolled for the study.
- There was significant reduction in incidence of the primary endpoints in the deferred group.
 - Slow flow/no reflow
 - There were also fewer thrombotic events
 - Final TIMI flow was higher.
 - higher salvaged myocardium on CMR





- On the contrary, the DANAMI 3-DEFER trial **failed** to show any benefit of deferred stenting on **clinical outcomes**.
- About 1,200 patients were randomised to a deferred stent strategy versus an immediate stenting technique.
- There was no significant difference in the primary outcome
- In addition, there was a slightly higher, although not significant, chance of reocclusion rates (2%) in the deferred stenting group.
- However, there was an insignificant improvement in LVEF in the deferred stenting group.
- An MRI sub-study also failed to find any benefit on myocardial infarct size, microvascular obstruction and myocardial salvage index.
- However, in patients with lesion length/stent >24 mm, the deferred strategy significantly reduced infarct size.






- Why are there contrasting results from two large RCTs on deferred PCI?
 - First, the DEFER STEMI enrolled patients at high risk of slow flow based on clinical angiographic features, whereas DANAMI 3-DEFER was an all-comer primary PCI study. A deferral strategy should only be applied after careful angiographic selection.
 - Second, DEFER STEMI was an angiographic and MRI endpoint study whereas DANAMI 3-DEFER looked at clinical outcomes.
 We know that clinical outcomes are affected by many variables and imaging features are only one of the facets.
 - Third, DANAMI 3-DEFER was a larger, multicentre, randomised study, in contrast to DEFER, which was a small, single-centre, proof of concept study.
 - Fourth, the use of GPIIb/IIIa inhibitors in DANAMI 3-DEFER was significantly lower compared to DEFER STEMI.





- The INNOVATION study did not find any merit in a routine defer strategy during primary PCI at two centres in South Korea.
- In the subset of anterior infarction, the primary endpoint — infarct size and microvascular obstruction — was significantly attenuated.

Graphical abstract







- The DS group showed:
 - Significantly lower rate of stent implantation and a
 - Higher use of thrombus aspiration and
 - Higher use of GP IIb/IIIa inhibitors.
- No significant differences were observed between the groups in terms of all-cause mortality or MACCE.





- A meta-analysis by Freixa et al., which encompasses six studies, 283 patients:
 - Three coronary reocclusions occurring
 - Improved left ventricular function
 - Lower MACE rate.
- Subsequently, Qiao et al. in their meta-analyses of nine studies found:
 - No difference in incidence of slow flow/no reflow
 - Improvement in LVEF in the long term
 - No difference in MACE.













What Should Be the Ideal Deferral Time?

- A 7-day deferral is plausible with additional thrombus attenuation and improved periprocedural advantages though only a minority of RCTs enrolled such patients.
- Administer IV GPIIb/IIIa inhibitor for 12–16 hours after the procedure followed by low molecular weight heparin for 5–7 days or until the next angiogram depending upon the baseline CRUSADE score.
- In patients with a CRUSADE score >20, the GP IIb/IIIa infusion is avoided and only intracoronary bolus is provided.
- For those at score >50, the duration of heparin is also reduced.









Future Directions

• INNOVATIONCORE (NCT03744000): 2024

To evaluate the impact of deferred versus immediate stenting in patients with acute ST-segment elevation anterior wall myocardial infarction (STEMI)

OPTIMAL(NCT03282773): 2022

The OPTIMAL study is designed to compare the clinical performance of deferred stenting with that of immediate stenting for AMI caused by left main coronary artery occlusion.







.



thc.tums.ac.ir